TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an Agreement with Fortified Provider Network (Fortified), a …
It’s a tale of two biotech firms this afternoon, as shares of TrovaGene Inc (NASDAQ:TROV) are up $0.73, or 20%, at $4.
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced that it has entered into an agreement with FedMed, Inc. (FedMed) establishing health benefit …
While U.S.
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with America’s Choice Provider Network …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that the U.S.
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, …
Trovagene, Inc. (NASDAQ:TROV), a leading enterprise software company for brand advertising, announced the launch of its new cross-screen planning technology.
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, today announced the presentation of clinical data featuring the use of its Precision Cancer Monitoring℠ …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today the presentation of clinical results featuring the use of its Precision Cancer Monitoring℠ …
